Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 17029
Country/Region: South Africa
Year: 2014
Main Partner: Witkoppen Health And Welfare Centre
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $1,761,039 Additional Pipeline Funding: $484,908

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

Witkoppen Health and Welfare Centre (WHWC) is an integrated health and welfare facility in the northern suburbs of Johannesburg, which offers a variety of programs in response to the needs of our beneficiaries, most of whom live in informal settlements.

The HIV/AIDS program at WHWC started in 1996 in response to a need of our beneficiaries who were very ill and dying in the communities. USAID funding for this program was first received in 2004, through Right to Care. This program, entitled: “Innovative Approaches to Integrated Primary Health Care for Marginalized, At-Risk Populations in Informal Settlements in Urban South Africa,” has two goals: to build capacity and support for scale-up of effective and efficient models for HIV-related services in line with SAG priorities; and, to develop, evaluate, scale-up, and institutionalize innovations to inform SAG strategies for improving treatment outcomes among key populations such as pregnant women, infants, children, adolescents, people residing in informal settlements, and those who are HIV/TB co-infected. The objectives of the program are: to provide interim primary care, support, and referral services to residents of informal settlements, targeting an under-serviced population; to increase DOH service-delivery capacity in the WHWC catchment area; to implement effective cost efficient innovative approaches to integrate primary care for HIV and TB/HIV; to inform DOH on the evaluation findings; and, to inform SAG policy to facilitate the introduction of National Health Insurance. WHWC conducts operational research to inform the health sector nationally and internationally on effective and cost efficient innovations and institutionalizes such strategies.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $336,382
Care: TB/HIV (HVTB) $180,885
Care: Pediatric Care and Support (PDCS) $155,333
Strategic Information (HVSI) $0
Testing: HIV Testing and Counseling (HVCT) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $227,592
Treatment: Adult Treatment (HTXS) $695,036
Treatment: Pediatric Treatment (PDTX) $165,811
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Age/sex: <1 Female 2015 167
HTS_TST Age/sex: <1 Female 2015 527
HTS_TST Age/sex: <1 Male 2015 177
HTS_TST Age/sex: <1 Male 2015 565
HTS_TST Age/sex: 1-4 Female 2015 102
HTS_TST Age/sex: 1-4 Female 2015 324
HTS_TST Age/sex: 1-4 Male 2015 102
HTS_TST Age/sex: 1-4 Male 2015 322
HTS_TST Age/sex: 10-14 Female 2015 36
HTS_TST Age/sex: 10-14 Female 2015 113
HTS_TST Age/sex: 10-14 Male 2015 24
HTS_TST Age/sex: 10-14 Male 2015 76
HTS_TST Age/sex: 15-19 Female 2015 54
HTS_TST Age/sex: 15-19 Female 2015 170
HTS_TST Age/sex: 15-19 Male 2015 25
HTS_TST Age/sex: 15-19 Male 2015 80
HTS_TST Age/sex: 20-24 Female 2015 200
HTS_TST Age/sex: 20-24 Female 2015 633
HTS_TST Age/sex: 20-24 Male 2015 111
HTS_TST Age/sex: 20-24 Male 2015 352
HTS_TST Age/sex: 25-49 Female 2015 893
HTS_TST Age/sex: 25-49 Female 2015 2,827
HTS_TST Age/sex: 25-49 Male 2015 731
HTS_TST Age/sex: 25-49 Male 2015 2,314
HTS_TST Age/sex: 5-9 Female 2015 57
HTS_TST Age/sex: 5-9 Female 2015 179
HTS_TST Age/sex: 5-9 Male 2015 55
HTS_TST Age/sex: 5-9 Male 2015 175
HTS_TST Age/sex: 50+ Female 2015 302
HTS_TST Age/sex: 50+ Female 2015 957
HTS_TST Age/sex: 50+ Male 2015 128
HTS_TST Age/sex: 50+ Male 2015 406
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 361
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 1,143
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 359
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 1,136
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 1,449
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 4,589
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 995
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 3,152
HTS_TST By Test Result: Negative 2015 2,665
HTS_TST By Test Result: Negative 2015 8,438
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 3,164
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 10,020
HTS_TST Sum of Age/Sex disaggregates 2015 3,164
HTS_TST Sum of Age/Sex disaggregates 2015 10,020
HTS_TST Sum of Aggregated Age/Sex <15 2015 720
HTS_TST Sum of Aggregated Age/Sex <15 2015 2,279
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 2,444
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 7,741
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 3,164
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 10,020
HTS_TST Sum of Test Result disaggregates 2015 3,164
HTS_TST Sum of Test Result disaggregates 2015 10,020
HTS_TST_POS By Test Result: Positive 2015 499
HTS_TST_POS By Test Result: Positive 2015 1,582
PMTCT_ARV Life-long ART (including Option B+) 2015 364
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 440
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 364
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 95
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 269
PMTCT_ARV Sum of New and Current disaggregates 2015 364
PMTCT_ARV Sum of Regimen Type disaggregates 2015 364
PMTCT_EID By infants who received a virologic test within 2 months of birth 2015 18
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2015 292
PMTCT_EID By infants with a positive virologic test result within 12 months of birth 2015 3
PMTCT_EID Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) 2015 443
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2015 310
PMTCT_EID Sum of Infant Age disaggregates 2015 310
PMTCT_STAT By: Known positives at entry 2015 121
PMTCT_STAT By: Number of new positives identified 2015 322
PMTCT_STAT Number of new ANC and L&D clients 2015 1,813
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 1,799
PMTCT_STAT Sum of Positives Status disaggregates 2015 443
TX_CURR Age/Sex: <1 Female 2015 1
TX_CURR Age/Sex: <1 Female 2015 2
TX_CURR Age/Sex: <1 Male 2015 1
TX_CURR Age/Sex: <1 Male 2015 1
TX_CURR Age/Sex: 1-4 Female 2015 8
TX_CURR Age/Sex: 1-4 Female 2015 25
TX_CURR Age/Sex: 1-4 Male 2015 7
TX_CURR Age/Sex: 1-4 Male 2015 23
TX_CURR Age/Sex: 15+ Female 2015 700
TX_CURR Age/Sex: 15+ Female 2015 2,217
TX_CURR Age/Sex: 15+ Male 2015 324
TX_CURR Age/Sex: 15+ Male 2015 1,028
TX_CURR Age/Sex: 5-14 Female 2015 21
TX_CURR Age/Sex: 5-14 Female 2015 66
TX_CURR Age/Sex: 5-14 Male 2015 18
TX_CURR Age/Sex: 5-14 Male 2015 56
TX_CURR Aggregated Age/Sex: <1 Female 2015 1
TX_CURR Aggregated Age/Sex: <1 Female 2015 2
TX_CURR Aggregated Age/Sex: <1 Male 2015 1
TX_CURR Aggregated Age/Sex: <1 Male 2015 1
TX_CURR Aggregated Age/Sex: <15 Female 2015 30
TX_CURR Aggregated Age/Sex: <15 Female 2015 93
TX_CURR Aggregated Age/Sex: <15 Male 2015 26
TX_CURR Aggregated Age/Sex: <15 Male 2015 80
TX_CURR Aggregated Age/Sex: 15+ Female 2015 700
TX_CURR Aggregated Age/Sex: 15+ Female 2015 2,217
TX_CURR Aggregated Age/Sex: 15+ Male 2015 324
TX_CURR Aggregated Age/Sex: 15+ Male 2015 1,028
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 1,080
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 3,418
TX_CURR Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 10
TX_CURR Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 29
TX_CURR Sum of age/sex disaggregates 2015 173
TX_CURR Sum of Age/Sex disaggregations 2015 56
TX_CURR Sum of Aggregated Age/Sex <15 2015 56
TX_CURR Sum of Aggregated Age/Sex <15 2015 173
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 1,024
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 3,245
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 1,080
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 3,418
TX_NEW Aggregated Grouping by Age: <1 Male 2015 1
TX_NEW Aggregated Grouping by Age/Sex: <1 Female 2015 3
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2015 51
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2015 29
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2015 1,431
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2015 822
TX_NEW By Age/Sex: <1 Female 2015 3
TX_NEW By Age/Sex: <1 Male 2015 1
TX_NEW By Age/Sex: 1-4 Female 2015 22
TX_NEW By Age/Sex: 1-4 Male 2015 14
TX_NEW By Age/Sex: 10-14 Female 2015 13
TX_NEW By Age/Sex: 10-14 Male 2015 8
TX_NEW By Age/Sex: 15-19 Female 2015 20
TX_NEW By Age/Sex: 15-19 Male 2015 6
TX_NEW By Age/Sex: 20-24 Female 2015 160
TX_NEW By Age/Sex: 20-24 Male 2015 23
TX_NEW By Age/Sex: 25-49 Female 2015 1,153
TX_NEW By Age/Sex: 25-49 Male 2015 721
TX_NEW By Age/Sex: 5-9 Female 2015 13
TX_NEW By Age/Sex: 5-9 Male 2015 6
TX_NEW By Age/Sex: 50+ Female 2015 98
TX_NEW By Age/Sex: 50+ Male 2015 72
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2015 2,333
TX_NEW Pregnancy status 2015 161
TX_NEW Sum of Age/Sex disaggregates 2015 2,333
TX_NEW Sum of Aggregated Age/Sex disaggregates 2015 2,333
TX_RET Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 25
TX_RET Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 1,071
TX_RET Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 33
TX_RET Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 58
TX_RET Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 1,071
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2015 1,129
TX_RET Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 78
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2015 1,412
TX_RET_den Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 31
TX_RET_den Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 1,340
TX_RET_den Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 41
TX_RET_den Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 72
TX_RET_den Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 1,340
TX_RET_den Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 97
Cross Cutting Budget Categories and Known Amounts Total: $354,547
Gender: Gender Equality $309,667
Changing harmful gender norms and promoting positive gender norms
Implementation
Operation Research
Equity in HIV prevention, care, treatment and support
Implementation
Operation Research
Food and Nutrition: Policy, Tools, and Service Delivery $14,121
Condoms: Policy, Tools, and Services $30,759
Key Issues Identified in Mechanism
Child Survival Activities
Mobile Populations
Safe Motherhood
Tuberculosis
Family Planning